GHO Capital

GHO Capital is a London-based healthcare-dedicated growth and buyout investment firm with a substantial multi-billion-dollar platform investing in established healthcare businesses across pharma services, medical technology, healthcare services, and health and wellness. The ghocapital.com website confirms a private equity specialist focused on revenue-stage and profitable businesses, not early-stage venture. For healthcare AI founders, GHO Capital is the right type of investor only if you are running a substantial, profitable healthcare business with proven economics and a path to control or significant growth equity transactions. This is not a venture investor at any stage. Plausible check sizes run 50M to 250M plus for control or significant minority positions in healthcare businesses with substantial revenue, often 30M plus EBITDA. Founders running healthcare AI services companies with substantial scale, healthcare technology platforms with proven payer or provider contracts, or rollup-amenable healthcare businesses augmented with AI should approach. Founders at seed, Series A, B, or C stages should not approach; the platform does not invest at venture stage. Founders building research-stage AI or pre-revenue technology should look at venture-stage life sciences or healthcare AI specialists. Entry path is warm introduction through healthcare investment bankers (Jefferies, Lazard, William Blair healthcare teams), healthcare services operators, or portfolio CEOs. GHO operates through banker-led processes rather than open submissions; cold approaches are not the norm at this scale. Diligence will be private equity-grade: deep operational, financial, regulatory, and reimbursement diligence over months. Expect a thorough, slow process oriented around control or significant minority transactions. The healthcare specialization is real, and the value-add is meaningful for businesses at the right scale.